⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy

Official Title: Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy

Study ID: NCT00000807

Interventions

Etoposide

Study Description

Brief Summary: To assess the toxicity, tumor response rate, and effect on quality of life of daily low-dose etoposide administered for 7 consecutive days every other week in patients with AIDS-related Kaposi's sarcoma that has relapsed or progressed after systemic chemotherapy. Etoposide may be at least as, or even more, effective and less myelotoxic when given in low doses over prolonged periods of time.

Detailed Description: Etoposide may be at least as, or even more, effective and less myelotoxic when given in low doses over prolonged periods of time. Patients receive low-dose oral etoposide on days 1 through 7 of every 2-week cycle. Patients who achieve a complete or partial response after two cycles and have no toxicity greater than grade 2 may have their dose escalated for subsequent cycles. If there are no responses to therapy among the first 14 evaluable patients, the study will close; if there is at least one objective response to therapy among the first 14 evaluable patients, enrollment will continue until all 41 patients are enrolled. Patients continue therapy until maximal tumor response (either stable disease or complete response) is achieved or disease progression occurs.

Eligibility

Minimum Age: 12 Years

Eligible Ages: CHILD, ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Univ of Alabama at Birmingham, Birmingham, Alabama, United States

K Norris Cancer Hosp / Los Angeles County - USC Med Ctr, Los Angeles, California, United States

Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States

San Francisco Gen Hosp, San Francisco, California, United States

Denver Dept of Health and Hosps, Denver, Colorado, United States

Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States

Yale Univ / New Haven, New Haven, Connecticut, United States

Univ of Miami School of Medicine, Miami, Florida, United States

Northwestern Univ Med School, Chicago, Illinois, United States

Indiana Univ Hosp, Indianapolis, Indiana, United States

Boston Med Ctr, Boston, Massachusetts, United States

Adirondack Med Ctr at Saranac Lake, Albany, New York, United States

Albany Med College / Division of HIV Medicine A158, Albany, New York, United States

Mid - Hudson Care Ctr, Albany, New York, United States

SUNY / Erie County Med Ctr at Buffalo, Buffalo, New York, United States

City Hosp Ctr at Elmhurst / Mount Sinai Hosp, Elmhurst, New York, United States

Saint Clare's Hosp and Health Ctr, New York, New York, United States

Mount Sinai Med Ctr, New York, New York, United States

Columbia Presbyterian Med Ctr, New York, New York, United States

Julio Arroyo, West Columbia, South Carolina, United States

Contact Details

Name: Von Roenn JH

Affiliation:

Role: STUDY_CHAIR

Name: Paredes J

Affiliation:

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: